----

----

| x      | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     |
|--------|------------------------------------------------------------------------------------------|
|   |                                                                                     |
|   | For the fiscal year ended April 30, 2010                                                 |
|   |                                                                                     |
|   | OR                                                                                       |
|   |                                                                                     |
|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   | Large accelerated filer |  ̈ |   | Accelerated filer         |  ̈ |
|--------|-------------------------|--------|--------|---------------------------|--------|
|   |                    |   |   |                      |   |
|   | Non-accelerated filer   |  ̈ |   | Smaller reporting company | x      |

----

----

|   | · | Restate the date and number of common shares outstanding; |
|--------|--------|-----------------------------------------------------------|

|   | · | Adjust the layout and format for FS table F-3 and F-4; |
|--------|--------|--------------------------------------------------------|

|   | · | Amend the words contained under Item 2 – Cash Flow; |
|--------|--------|-----------------------------------------------------------|

|   | · | Revise the Recent Accounting Pronouncements under Item 2; |
|--------|--------|-----------------------------------------------------------|

|   | · | Amend the words contained under Item 4 – Evaluation of Disclosure Controls and Procedures. |
|--------|--------|--------------------------------------------------------------------------------------------------|

----

----

----

|                                                                                                                                                                                                                                     | Pages         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
|                                                                                                                                                                                                                                     |          |
|                                                                                                                                                                                                                                     |          |
| Condensed Consolidated Balance Sheets as of April 30, 2010 (unaudited) and October 31, 2009                                                                                                                                              | F-1           |
|                                                                                                                                                                                                                                     |          |
|                                                                                                                                                                                                                                     |          |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months and six months ended April 30, 2010 and 2009 (unaudited) and the period from inception September 25, 2002 through April 30, 2010 (unaudited) | F-2           |
|                                                                                                                                                                                                                                     |          |
|                                                                                                                                                                                                                                     |          |
| Condensed Consolidated Statements of Stockholders’ Deficiency for the period from inception September 25, 2002 through April 30, 2010 (unaudited)                                                                                  | F-3           |
|                                                                                                                                                                                                                                     |          |
|                                                                                                                                                                                                                                     |          |
| Condensed Consolidated Statements of Cash Flows for the six months ended April 30, 2010 and 2009 (unaudited) and the period from inception September 25, 2002 through April 30, 2010 (unaudited)                                         | F-4           |
|                                                                                                                                                                                                                                     |          |
|                                                                                                                                                                                                                                     |          |
| Notes to Condensed Consolidated Financial Statements (unaudited)                                                                                                                                                                         | F5 – F9 |
|                                                                                                                                                                                                                                     |          |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. ("ABMT") |
|-------------------------------------------------|
|  AND SUBSIDIARIES                          |
| (A DEVELOPMENT STAGE COMPANY)                   |
| CONDENSED CONSOLIDATED BALANCE SHEETS           |
|                                            |   |   |   |   |   |   |   |   |   |
|                                            |   |   |   |   |   |   |   |   |   |

| ASSETS                                                                                                                                                                                                |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                  |   | April 30, |   |   | October 31, |   |
|                                                                                                                                                                                                  |   | 2010 |   |   | 2009 |   |
|                                                                                                                                                                                                  |   | Unaudited |   |   |   |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |
| CURRENT ASSETS                                                                                                                                                                                        |   |   |   |   |   |   |
| Cash and cash equivalents                                                                                                                                                                             |   | $ | 49,674 |   |   | $ | 10,606 |   |
| Other receivables and prepaid expenses                                                                                                                                                                |   |   | 22,729 |   |   |   | 20,473 |   |
| Total Current Assets                                                                                                                                                                                  |   |   | 72,403 |   |   |   | 31,079 |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| PROPERTY AND EQUIPMENT, NET                                                                                                                                                                           |   |   | 59,658 |   |   |   | 70,088 |   |
| TOTAL ASSETS                                                                                                                                                                                          |   | $ | 132,061 |   |   | $ | 101,167 |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                                                                                                 |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                                                                                                                                   |   |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                                                                                                                                                   |   | $ | 15,428 |   |   | $ | 30,657 |   |
| Due to a stockholder                                                                                                                                                                                  |   |   | 204,157 |   |   |   | 335,755 |   |
| Due to directors                                                                                                                                                                                      |   |   | 173,244 |   |   |   | 220,894 |   |
| Due to a related company                                                                                                                                                                              |   |   | 390,591 |   |   |   | 390,459 |   |
| Due to related parties                                                                                                                                                                                |   |   | 600,171 |   |   |   | 386,159 |   |
| Total Current Liabilities                                                                                                                                                                             |   |   | 1,383,591 |   |   |   | 1,363,924 |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                                                                                                                                         |   |   | - |   |   |   | - |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| DEFICIT                                                                                                                                                                                               |   |   |   |   |   |   |   |   |
| ABMT Stockholders' Deficit                                                                                                                                                                            |   |   |   |   |   |   |   |   |
| Common stock, $0.00001 par value, 100,000,000 shares authorized and 55,744,334 shares issued and outstanding as of April 30, 2010 and 55,721,000 shares issued and outstanding as of October 31, 2009 |   |   | 557 |   |   |   | 557 |   |
| Common stock, 136,833 shares to be issued                                                                                                                                                             |   |   | 1 |   |   |   | - |   |
| Additional paid-in capital                                                                                                                                                                            |   |   | 986,579 |   |   |   | 732,269 |   |
| Deferred stock compensation                                                                                                                                                                           |   |   | (216,042 | ) |   |   | (292,292 | ) |
| Accumulated deficit during development stage                                                                                                                                                          |   |   | (1,938,465 | ) |   |   | (1,619,245 | ) |
| Accumulated other comprehensive loss                                                                                                                                                                  |   |   | (84,160 | ) |   |   | (84,046 | ) |
| Total ABMT Stockholders' Deficit                                                                                                                                                                      |   |   | (1,251,530 | ) |   |   | (1,262,757 | ) |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |
| Noncontrolling interests                                                                                                                                                                              |   |   | - |   |   |   | - |   |
| Total Deficit                                                                                                                                                                                         |   |   | (1,251,530 | ) |   |   | (1,262,757 | ) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                                                                                           |   | $ | 132,061 |   |   | $ | 101,167 |   |
|                                                                                                                                                                                                  |   |   |   |   |   |   |   |   |

|                                                                                             |   |   |   |   |   |   |   |   |   |
|--------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| The accompanying notes are an integral part of these condensed consolidated financial statements |
|                                                                                             |   |   |   |   |   |   |   |   |   |
| F-1                                                                                              |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                |
|------------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                          |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| (UNAUDITED)                                                            |

|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |
|-------------------------------------------------------------------------------------|--------|--------------------|------------|--------|------------------|--------|------------|---------------------|--------|--------|------------|--------|--------|----------------|------------|
|                                                                                |   | Three months ended |       |   | Six months ended |   |       | September 25, 2002  |   |
|                                                                                |   | April 30,          |       |   | April 30,        |   |       | (Inception) through |   |
|                                                                                |   | 2010               |       |   | 2009             |   |       | 2010                |   |   | 2009       |   |   | April 30, 2010 |       |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |
| OPERATING EXPENSES                                                                  |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |
| General and administrative expenses                                                 |   | $                  | 112,600    |   |             | $      | 122,709    |                |   | $      | 257,200    |   |   | $              | 230,120    |   |   | $ | 1,552,359 |   |
| Depreciation                                                                        |   |               | 7,387      |   |             |   | 7,926      |                |   |   | 14,839     |   |   |           | 16,478     |   |   |   | 251,644 |   |
| Research and development (Net of government grant)                             |   |               | -          |   |             |   | 3,378      |                |   |   | 1,840      |   |   |           | 3,378      |   |   |   | 109,187 |   |
| Total Operating Expenses                                                            |   |               | 119,987    |   |             |   | 134,013    |                |   |   | 273,879    |   |   |           | 249,976    |   |   |   | 1,913,190 |   |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| LOSS FROM OPERATIONS                                                                |   |               | (119,987   | )      |             |   | (134,013   | )                   |   |   | (273,879   | )      |   |           | (249,976   | ) |   |   | (1,913,190 | ) |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| OTHER INCOME (EXPENSES)                                                             |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| Other income                                                                        |   |               | -          |   |             |   | -          |                |   |   | -          |   |   |           | -          |   |   |   | 1,976 |   |
| Interest income                                                                     |   |               | 23         |   |             |   | 18         |                |   |   | 36         |   |   |           | 57         |   |   |   | 1,534 |   |
| Interest paid to a stockholder and related parties                                  |   |               | (15,698    | )      |             |   | (8,623     | )                   |   |   | (28,529    | )      |   |           | (13,740    | ) |   |   | (69,652 | ) |
| Imputed interest                                                                    |   |               | (6,673     | )      |             |   | (7,925     | )                   |   |   | (14,061    | )      |   |           | (15,981    | ) |   |   | (162,789 | ) |
| Other expenses                                                                      |   |               | (2,494     | )      |             |   | (286       | )                   |   |   | (2,787     | )      |   |           | (378       | ) |   |   | (13,549 | ) |
| Total Other Expenses, net                                                           |   |               | (24,842    | )      |             |   | (16,816    | )                   |   |   | (45,341    | )      |   |           | (30,042    | ) |   |   | (242,480 | ) |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| LOSS FROM OPERATIONS BEFORE TAXES                                                   |   |               | (144,829   | )      |             |   | (150,829   | )                   |   |   | (319,220   | )      |   |           | (280,018   | ) |   |   | (2,155,670 | ) |
| Income tax expense                                                                  |   |               | -          |   |             |   | -          |                |   |   | -          |   |   |           | -          |   |   |   | - |   |
| NET LOSS                                                                            |   |               | (144,829   | )      |             |   | (150,829   | )                   |   |   | (319,220   | )      |   |           | (280,018   | ) |   |   | (2,155,670 | ) |
| Net loss attributable to noncontrolling interests                                   |   |               | -          |   |             |   | -          |                |   |   | -          |   |   |           | -          |   |   |   | 217,205 |   |
| NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS                                   |   |               | (144,829   | )      |             |   | (150,829   | )                   |   |   | (319,220   | )      |   |           | (280,018   | ) |   |   | (1,938,465 | ) |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| OTHER COMPREHENSIVE LOSS                                                            |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| Total other comprehensive loss                                                      |   |               | (158       | )      |             |   | (1,723     | )                   |   |   | (114       | )      |   |           | (1,958     | ) |   |   | (84,160 | ) |
| Add: foreign currency translation loss attributable to noncontrolling interest      |   |               | -          |   |             |   | -          |                |   |   | -          |   |   |           | -          |   |   |   | - |   |
| Foreign currency translation loss attributable to ABMT common stockholders          |   |               | (158       | )      |             |   | (1,723     | )                   |   |   | (114       | )      |   |           | (1,958     | ) |   |   | (84,160 | ) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS                         |   | $                  | (144,987   | )      |             | $      | (152,552   | )                   |   | $      | (319,334   | )      |   | $              | (281,976   | ) |   | $ | (2,022,625 | ) |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| Net loss per share-basic and diluted                                                |   | $                  | (0.00      | )      |             | $      | (0.00      | )                   |   | $      | (0.01      | )      |   | $              | (0.01      | ) |   |   |   |   |
|                                                                                |   |               |       |   |             |   |       |                |   |   |       |   |   |           |       |   |   |   |   |   |
| Weighted average number of shares outstanding during the period - basic and diluted |   |               | 55,813,519 |   |             |   | 55,614,000 |                |   |   | 55,775,130 |   |   |           | 53,875,274 |   |   |   |   |   |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |
| F-2                                                                                              |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                         |
|---------------------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                                   |
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY (UNAUDITED) |
|                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |
|------------------------------------------------------------------------------------|--------|--------------|------------|--------|---------------------------|--------|--------|------------|--------|--------|----------|--------|--------|----------------|--------|--------|--------------|--------|---------|-------------|--------|--------|---------------|--------|--------|----------------|------------|--------|--------|--------|
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    | Accumulated |   |   | Accumulated   |   |   |           |       |   |   |   |
|                                                                               |   | Common Stock |       |   | Common Stock to be issued |   |   | Additional |   |   | Deferred |   |   | deficit during |   |   | other        |   |    |        |   |   |          |   |
|                                                                               |   | Number       |       |   |                      |   |   | Number     |   |   |     |   |   | Paid-in        |   |   | Stock        |   |    | development |   |   | comprehensive |   |   | Noncontrolling |       |   |   |   |
|                                                                               |   | of Shares    |       |   | Amount                    |   |   | of Shares  |   |   | Amount   |   |   | capital        |   |   | Compensation |   |    | stage       |   |   | loss          |   |   | interests      |       |   | Total  |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |
| Stock issued to founders for cash                                                  |   |         | 50,510,000 |   |                      | $      | 505    |       |   |   | -        |   |   |           | -      |   |         | $      | 275,002 |        |   | $      | -             |   |   | $              | -          |   |   | $      | - |   |   | $ | 217,205 |   |   | $ | 492,712 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                            |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (40,343    | )      |   |   | - |   |   |   | (17,290 | ) |   |   | (57,633 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (225 | ) |   |   | 10 |   |   |   | (215 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (57,848 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2003                                                       |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 275,002 |        |   |   | -             |   |   |           | (40,343    | )      |   |   | (225 | ) |   |   | 199,925 |   |   |   | 434,864 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (65,960    | )      |   |   | - |   |   |   | (28,269 | ) |   |   | (94,229 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (357 | ) |   |   | 2 |   |   |   | (355 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (94,584 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2004                                                       |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 275,002 |        |   |   | -             |   |   |           | (106,303   | )      |   |   | (582 | ) |   |   | 171,658 |   |   |   | 340,280 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 23,103  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 23,103 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (357,863   | )      |   |   | - |   |   |   | (153,370 | ) |   |   | (511,233 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (12,290 | ) |   |   | 2,064 |   |   |   | (10,226 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (521,459 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2005                                                       |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 298,105 |        |   |   | -             |   |   |           | (464,166   | )      |   |   | (12,872 | ) |   |   | 20,352 |   |   |   | (158,076 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 27,184  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 27,184 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (172,738   | )      |   |   | - |   |   |   | (18,276 | ) |   |   | (191,014 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (6,084 | ) |   |   | (2,076 | ) |   |   | (8,160 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (199,174 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2006                                                       |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 325,289 |        |   |   | -             |   |   |           | (636,904   | )      |   |   | (18,956 | ) |   |   | - |   |   |   | (330,066 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder, related company and related party |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 39,021  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 39,021 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (196,871   | )      |   |   | - |   |   |   | - |   |   |   | (196,871 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (27,401 | ) |   |   | - |   |   |   | (27,401 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (224,272 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2007                                                       |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 364,310 |        |   |   | -             |   |   |           | (833,775   | )      |   |   | (46,357 | ) |   |   | - |   |   |   | (515,317 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 27,764  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 27,764 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                            |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (227,038   | )      |   |   | - |   |   |   | - |   |   |   | (227,038 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (35,833 | ) |   |   | - |   |   |   | (35,833 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (262,871 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31,2008                                                         |   |         | 50,510,000 |   |                      |   | 505    |       |   |   | -        |   |   |           | -      |   |         |   | 392,074 |        |   |   | -             |   |   |           | (1,060,813 | )      |   |   | (82,190 | ) |   |   | - |   |   |   | (750,424 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Recapitalization                                                                   |   |         | 5,104,000  |   |                      |   | 51     |       |   |   | -        |   |   |           | -      |   |         |   | (51     | )           |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services                                                          |   |         | 100,000    |   |                      |   | 1      |       |   |   | -        |   |   |           | -      |   |         |   | 304,999 |        |   |   | (292,292      | )      |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 12,708 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                                         |   |         | 5,000      |   |                      |   | 0      |       |   |   | -        |   |   |           | -      |   |         |   | 5,750   |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 5,750 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                                         |   |         | 2,000      |   |                      |   | 0      |       |   |   | -        |   |   |           | -      |   |         |   | 2,300   |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 2,300 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Contributed capital                                                                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 26,950  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 26,950 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Distributed to the stockholders                                                    |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | (31,409 | )           |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (31,409 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 31,656  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 31,656 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (558,432   | )      |   |   | - |   |   |   | - |   |   |   | (558,432 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (1,856 | ) |   |   | - |   |   |   | (1,856 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (560,288 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2009                                                        |   |         | 55,721,000 |   |                      |   | 557    |       |   |   | -        |   |   |           | -      |   |         |   | 732,269 |        |   |   | (292,292      | )      |   |           | (1,619,245 | )      |   |   | (84,046 | ) |   |   | - |   |   |   | (1,262,757 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services                                                          |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | 76,250        |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 76,250 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                                         |   |         | 6,667      |   |                      |   | 0      |       |   |   | -        |   |   |           | -      |   |         |   | 10,000  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 10,000 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement                                         |   |         | 16,667     |   |                      |   | 0      |       |   |   | -        |   |   |           | -      |   |         |   | 25,000  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 25,000 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock to be issued                                                                 |   |         | -          |   |                      |   | -      |       |   |   | 136,833  |   |   |           | 1      |   |         |   | 205,249 |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 205,250 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | 14,061  |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | 14,061 |   |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                            |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | (319,220   | )      |   |   | - |   |   |   | - |   |   |   | (319,220 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | (114 | ) |   |   | - |   |   |   | (114 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |         | -          |   |                      |   | -      |       |   |   | -        |   |   |           | -      |   |         |   | -       |        |   |   | -             |   |   |           | -          |   |   |   | - |   |   |   | - |   |   |   | (319,334 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at April 30, 2010                                                          |   |         | 55,744,334 |   |                      | $      | 557    |       |   |   | 136,833  |   |   | $              | 1      |   |         | $      | 986,579 |        |   | $      | (216,042      | )      |   | $              | (1,938,465 | )      |   | $      | (84,160 | ) |   | $ | - |   |   | $ | (1,251,530 | ) |
|                                                                               |   |         |       |   |                      |   |   |       |   |   |     |   |   |           |   |   |         |   |    |        |   |   |          |   |   |           |       |   |   |   |   |   |   |   |   |   |   |   |   |   |

|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|--------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| The accompanying notes are an integral part of these condensed consolidated financial statements |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| F-3                                                                                              |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES           |
|-------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                     |
|  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
|                                                              |   |   |   |   |   |   |   |   |   |   |
|                                                              |   |   |   |   |   |   |   |   |   |   |

|                                                                    |   | Six months ended |     |   | September 25, 2002  |   |
|-------------------------------------------------------------------------|--------|------------------|----------|--------|---------------------|--------|
|                                                                    |   | April 30,        |     |   | (inception) through |   |
|                                                                    |   | 2010             |     |   | 2009                |   |   | April 30, 2010 |   |
|                                                                    |   |             |     |   |                |   |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                    |   |             |     |   |                |   |   |   |   |
| Net loss                                                                |   | $                | (319,220 | )      |                | $      | (280,018 | ) |   | $ | (1,938,465 | ) |
| Adjustments to reconcile net loss to cash used in operating activities: |   |             |     |   |                |   |   |   |   |   |   |   |
| Depreciation                                                            |   |             | 14,839   |   |                |   | 16,478 |   |   |   | 251,644 |   |
| Stock issued for services                                               |   |             | 76,250   |   |                |   | - |   |   |   | 88,958 |   |
| Noncontrolling interests                                                |   |             | -        |   |                |   | - |   |   |   | (217,205 | ) |
| Imputed interest                                                        |   |             | 14,061   |   |                |   | 15,981 |   |   |   | 162,789 |   |
| Changes in operating assets and liabilities                             |   |             |     |   |                |   |   |   |   |   |   |   |
| Increase in:                                                            |   |             |     |   |                |   |   |   |   |   |   |   |
| Other receivables and prepaid expenses                                  |   |             | (2,252   | )      |                |   | (7,740 | ) |   |   | (22,729 | ) |
| Increase (decrease) in:                                                 |   |             |     |   |                |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                     |   |             | (15,232  | )      |                |   | (7,276 | ) |   |   | 15,428 |   |
| Net cash used in operating activities                                   |   |             | (231,554 | )      |                |   | (262,575 | ) |   |   | (1,659,580 | ) |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| Purchase of property and equipment                                      |   |             | (4,389   | )      |                |   | (14,267 | ) |   |   | (311,302 | ) |
| Net cash used in investing activities                                   |   |             | (4,389   | )      |                |   | (14,267 | ) |   |   | (311,302 | ) |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| Stock issued to founders                                                |   |             | -        |   |                |   | - |   |   |   | 505 |   |
| Proceeds from issuance of shares                                        |   |             | 240,250  |   |                |   | - |   |   |   | 248,300 |   |
| Contribution by stockholders                                            |   |             | -        |   |                |   | - |   |   |   | 519,157 |   |
| Distributed to stockholders                                             |   |             | -        |   |                |   | (31,408 | ) |   |   | (31,409 | ) |
| Due to a noncontrolling stockholder of a subsidiary                     |   |             | -        |   |                |   | 1,368 |   |   |   | - |   |
| Due to a stockholder                                                    |   |             | (131,411 | )      |                |   | 207,836 |   |   |   | 204,157 |   |
| Due to directors                                                        |   |             | (47,727  | )      |                |   | (12,476 | ) |   |   | 173,244 |   |
| Due to a related company                                                |   |             | -        |   |                |   | - |   |   |   | 390,591 |   |
| Due to related parties                                                  |   |             | 213,907  |   |                |   | 118,778 |   |   |   | 600,171 |   |
| Net cash provided by financing activities                               |   |             | 275,019  |   |                |   | 284,098 |   |   |   | 2,104,716 |   |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| EFFECT ON EXCHANGE RATES ON CASH                                        |   |             | (8       | )      |                |   | 673 |   |   |   | (84,160 | ) |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| NET INCREASE IN CASH AND CASH EQUIVALENTS                               |   |             | 39,068   |   |                |   | 7,929 |   |   |   | 49,674 |   |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                        |   |             | 10,606   |   |                |   | 78,876 |   |   |   | - |   |
|                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD                              |   | $                | 49,674   |   |                | $      | 86,805 |   |   | $ | 49,674 |   |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|
|                                                                                             |   |   |   |   |   |   |   |   |   |   |
| F-4                                                                                              |

----

| NOTE 1    | BASIS OF PRESENTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments consisting only of normal recurring accruals considered necessary to present fairly the Company's financial position as of April 30, 2010, the consolidated results of operations for the three months and six months ended April 30, 2010 and 2009 and for the period from September 25, 2002 (inception) to April 30, 2010 and consolidated statements of cash flows for the six months ended  April 30, 2010 and 2009 and for the period from September 25, 2002 (inception) to April 30, 2010. The consolidated results for the three months and six months ended April 30, 2010 are not necessarily indicative of the results to be expected for the entire fiscal year ending October 31, 2010. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2009 appearing in the Company's annual report on Form 10-K as filed with the Securities and Exchange Commission on February 12,  2010.                                                                          |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| NOTE 2    | ORGANIZATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or ”Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | Shenzhen Changhua Biomedicine Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the State Food and Drug Administration (“SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company. |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                     | On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua for the three months and six months ended April 30, 2010 and 2009 were included in the consolidated financial statements as if the transactions had occurred retroactively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

----

|   | On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.                                                                                                                                                                         |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | Accordingly, these financial statements include the following:                                                                                                                                                                                                                                                                                                                                                                                          |

|   | (1) | The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                     | ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”)                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| NOTE 3    | PRINCIPLES OF CONSOLIDATION                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.                                                                                                                 |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | All significant inter-company balances and transactions have been eliminated in consolidation.                                                                                                                                                                                                                                                                                                                                                       |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| NOTE 4                   | USE OF ESTIMATES                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| NOTE 5                   | RELATED PARTY TRANSACTIONS                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | As of April 30, 2010, the Company owed a stockholder $204,157 which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.                                                                                                                                                                                                                                                                                    |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | As of April 30, 2010, the Company owed two related parties a total of $600,171 which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.                                                                                                                                                                                                                                                                |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     | Total interest expenses on advances from a stockholder and the related parties accrued for the three months and six months ended April 30, 2010 and 2009 and for the period from September 25, 2002 (inception) through April 30, 2010 were $15,698, $8,623, $28,529, $13,740 and $69,652 respectively.                                                                                                                                              |

----

|                     | As of April 30, 2010, the Company owed $173,244 to three directors for advances made on an unsecured basis, repayable on demand and interest free.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | As of April 30, 2010, the Company owed $390,591 to a related company on an unsecured basis, repayable on demand and interest free.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | Imputed interest charged at 5% per annum on the amounts owed to three directors, and a related company is $6,673, $7,925, $14,061, $15,981 and $162,789 for the three months and six months ended April 30, 2010 and 2009 and for the period from September 25, 2002 (inception) through April 30, 2010 respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NOTE 6    | STOCKHOLDERS’ EQUITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | Common stock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | On December 19, 2009, the Company issued 23,334 shares of common stock at $1.50 per share for cash in a private placement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | On March 16, 2010, the Company entered into a subscription agreement with an investor for the issue of 136,833 shares of common stock at $1.50 per share for cash. The total subscription amount of $205,250 was received on March 16, 2010 and the 136,833 shares were issued to the investor on May 13, 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NOTE 7    | RECENT ACCOUNTING PRONOUNCEMENTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | In April 2010, FASB issued ASU 2010-13 Compensation-Stock Compensation (Topic 718) Effect of Denominating the Exercise Price of a Share-Based Payment Award in the Currency of the Market in Which the Underlying Equity Security Trades. ASU 2010-13 addresses the classification of a share-based payment award with an exercise price denominated in the currency of a market in which the underlying equity security trades. Topic 718 is amended to clarify that a share-based payment award with an exercise price denominated in the currency of a market in which a substantial portion of the entity’s equity securities trades shall not be considered to contain a market, performance, or service condition. Therefore, such an award is not to be classified as a liability if it otherwise qualifies as equity classification. The amendments in this Update should be effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2010. The guidance should be applied by recording a cumulative-effect adjustment to the opening balance of retained earnings for all outstanding awards as of the beginning of the fiscal year in which the amendments are initially applied. Management is currently evaluating the potential impact of ASU 2010-13 on our financial statements. |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | In March 2010, FASB issued ASU 2010-11 Derivatives and Hedging (Topic 815) Scope Exception Related to Embedded Credit Derivatives (“ASU 2010-11”). ASU 2010-11 clarifies the type of embedded credit derivative that is exempt from embedded derivative bifurcation requirements. Only one form of embedded credit derivative qualifies for the exemption—one that is related only to the subordination of one financial instrument to another. As a result, entities that have contracts containing an embedded credit derivative feature in a form other than such subordination may need to separately account for the embedded credit derivative feature. The amendments in this Update are effective for each reporting entity at the beginning of its first fiscal quarter beginning after June 15, 2010. Early adoption is permitted at the beginning of each entity’s first fiscal quarter beginning after issuance of this Update. The Management is currently evaluating the potential impact of ASU 2010-11 on our financial statements.                                                                                                                                                                                                                                                                                |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     | In February 2010, FASB issued ASU 2010-9 Subsequent Events (Topic 855) Amendments to Certain Recognition and Disclosure Requirements ("ASU 2010-9"). ASU 2010-9 amends disclosure requirements within Subtopic 855-10. An entity that is an SEC filer is not required to disclose the date through which subsequent events have been evaluated. This change alleviates potential conflicts between Subtopic 855-10 and the SEC's requirements. ASU 2010-9 is effective for interim and annual periods ending after June 15, 2010. The adoption of ASU 2010-9 did not have a material impact on our financial statements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

----

|                     | In January 2010, the FASB issued ASU 2010-06, Improving Disclosures about Fair Value Measurements. The ASU requires disclosing the amounts of significant transfers in and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers. The disclosures are effective for reporting periods beginning after December 15, 2009. Additionally, disclosures of the gross purchases, sales, issuances and settlements activity in Level 3 fair value measurements will be required for fiscal years beginning after December 15, 2010. The Company does not expect the provisions of ASU 2010-06 to have a material effect on the financial position, results of operations or cash flows of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     | In January 2010, the FASB issued Accounting Standards Update 2010-01, Equity (Topic 505): Accounting for Distributions to Shareholders with Components of Stock and Cash (A Consensus of the FASB Emerging Issues Task Force). This amendment to Topic 505 clarifies the stock portion of a distribution to shareholders that allows them to elect to receive cash or stock with a limit on the amount of cash that will be distributed is not a stock dividend for purposes of applying Topics 505 and 260. Effective for interim and annual periods ending on or after December 15, 2009, and would be applied on a retrospective basis. The Company does not expect the provisions of ASU 2010-01 to have a material effect on the financial position, results of operations or cash flows of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     | In October, 2009, the FASB issued ASU 2009-15, “Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance or Other Financing”, now codified under FASB ASC Topic 470 “Debt”, (“ASU 2009-15”), and provides guidance for accounting and reporting for own-share lending arrangements issued in contemplation of a convertible debt issuance.  At the date of issuance, a share-lending arrangement entered into on an entity’s own shares should be measured at fair value in accordance with Topic 820 and recognized as an issuance cost, with an offset to additional paid-in capital.  Loaned shares are excluded from basic and diluted earnings per share unless default of the share-lending arrangement occurs.  The amendments also require several disclosures including a description and the terms of the arrangement and the reason for entering into the arrangement.  The effective dates of the amendments are dependent upon the date the share-lending arrangement was entered into and include retrospective application for arrangements outstanding as of the beginning of fiscal years beginning on or after December 15, 2009.    The Company does not expect the provisions of ASU 2009-15 to have a material effect on the financial position, results of operations or cash flows of the Company. |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     | In October 2009, the FASB issued ASU 2009-14, “Certain Arrangements That Include Software Elements, now codified under FASB ASC Topic 985, “Software”, (“ASU 2009-14”). ASU 2009-14 removes tangible products from the scope of software revenue guidance and provides guidance on determining whether software deliverables in an arrangement that includes a tangible product are covered by the scope of the software revenue guidance. ASU 2009-14 should be applied on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, with early adoption permitted. The Company does not expect the provisions of ASU 2009-14 to have a material effect on the financial position, results of operations or cash flows of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     | In October 2009, the FASB issued ASU 2009-13, “Multiple-Deliverable Revenue Arrangements”, now codified under FASB ASC Topic 605, “Revenue Recognition”, (“ASU 2009-13”). ASU 2009-13 requires entities to allocate revenue in an arrangement using estimated selling prices of the delivered goods and services based on a selling price hierarchy. The amendments eliminate the residual method of revenue allocation and require revenue to be allocated using the relative selling price method. ASU 2009-13 should be applied on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, with early adoption permitted. The Company does not expect the provisions of ASU2009-13 to have a material effect on the financial position, results of operations or cash flows of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| NOTE 8    | GOING CONCERN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                     | As reflected in the accompanying unaudited condensed financial statements, the Company has an accumulated deficit of $1,938,465 at April 30, 2010 that includes a net loss of $319,220 for the six months ended April 30, 2010.  The Company’s total current liabilities exceeded its total current assets by $1,311,188 and the Company used cash in operations of $231,554. These factors raise substantial doubt about its ability to continue as a going concern.  In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying condensed balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

----

|   | ability to raise additional capital, obtain financing and succeed in its future operations.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.                                                                                                                               |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   | Management has taken the following steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern.  The Company is actively pursuing additional funding and strategic partners, which will enable the Company to implement its business plan.  Management believes that these actions as successful will allow the Company to continue its operations through the next fiscal year. |

----

----

|   | 1. | A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care; |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to 'stress shielding'; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | Reducing the chance of post-operative infection; |
|--------|----|--------------------------------------------------|

|   | 5. | Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries; |
|--------|----|---------------------------------------------------------------------------------------------------------------------|

|   | 6. | Ease of post-operative care i.e. no distortion during x-ray imaging; |
|--------|----|----------------------------------------------------------------------|

|   | 7. | Simple and cost-effective to manufacture. |
|--------|----|-------------------------------------------|

----

----

|    Estimate current production lines in full capacity |                                   |                                     |                                |
|----------------------------------------------------------------------|------------------------------------------|--------------------------------------------|---------------------------------------|
|                                                               |    Output Quantity (Max.) |    Price at ex-factory (U$) |    Total Turnover (U$) |
|    PA Screw                                           |    100,000                | (piece)                                    | 120                                   |   |      12,000,000 |   |
|    PA Binding Wire                                    |    240,000                | (pack)                                     | 50                                    |   |      12,000,000 |   |
|                                                               |                                   |                                     |                                | Total:    |      24,000,000 |   |

----

----

| Statistic and Census report by Ministry of Health of People's Republic of China.                        |
|---------------------------------------------------------------------------------------------------------|
| (Year 2008)                                                                                             |
|                                                                                                  |   |   |   |   | Total | Total |
|                                                                                                  | Total | Government | Society | Private | Non-Profit | Profit |
|   Hospitals                                                                                   | 19712 | 9777 | 6048 | 3887 | 15650 | 4038 |
|      General Hospital                                                          | 13119 | 5830 | 5060 | 2229 | 10856 | 2245 |
|      TCM Hospital                                                              | 2688 | 2244 | 158 | 286 | 2403 | 285 |
|      TCM-WM Hospital                                                           | 236 | 96 | 48 | 92 | 139 | 97 |
|      Minority Hospital                                                         | 191 | 170 | 8 | 13 | 175 | 16 |
|      Specialist Hospital                                                       | 3437 | 1422 | 763 | 1252 | 2048 | 1383 |
|      Nursing Hospital                                                          | 41 | 15 | 11 | 15 | 29 | 12 |
|                                                                                                  |   |   |   |   |   |   |
|   TCM Hospital:  Traditional Chinese Medicine Hospital                              |
|   WM Hospital:  Western Medicine Hospital                                    |
|   Minority Hospital:  The hospitals locate in Autonomous Region (Province) in China |

----

|                                             |   | Three months ended |   |   | Six months ended |   |   | September 25, 2002  |   |
|--------------------------------------------------|--------|--------------------|--------|--------|------------------|--------|--------|---------------------|--------|
|                                             |   | April 30,          |   |   | April 30,        |   |   | (Inception) through |   |
|                                             |   | 2010               |   |   | 2009             |   |   | 2010                |   |   | 2009 |   |   | April 30, 2010 |   |
|                                             |   |               |   |   |             |   |   |                |   |   |   |   |   |   |   |
| Interest paid to directors and a related company |   | $                  | (6,673 | )      |             |   | (7,925 | )                   |   |   | (14,061 | ) |   |   | (15,981 | ) |   |   | (162,789 | ) |

----

----

|   | 1. | Property and equipment |
|--------|----|------------------------|

|   | 2. | Long-lived assets |
|--------|----|-------------------|

|   | 3. | Fair value of financial instruments |
|--------|----|-------------------------------------|

|   | 4. | Government  grant |
|--------|----|-----------------------------|

|   | 5. | Income taxes |
|--------|----|--------------|

----

|   | 6. | Research and Development |
|--------|----|--------------------------|

|   | 7. | Foreign currency translation |
|--------|----|------------------------------|

----

----

----

| Exhibit No.   | Description                                            |
|-------------------------|--------------------------------------------------------|
|                    |                                                   |
| 3.1                     | Articles of Incorporation (1)                          |
|                    |                                                   |
| 3.2                     | Bylaws (1)                                             |
|                    |                                                   |
| 31.1                    | Section 302 Certification of Chief Executive Officer*  |
|                    |                                                   |
| 31.2                    | Section 302 Certification of Chief Financial Officer * |
|                    |                                                   |
| 32.1                    | Section 906 Certification of Chief Executive Officer * |
|                    |                                                   |
| 32.2                    | Section 906 Certification of Chief Financial Officer * |

----

| June 14, 2010 |   |   |
|---------------|--------|--------|
|          |   |   |
|          |   | By:    |
|          |   |   |
|          |   |   | ADVANCED BIOMEDICAL TECHNOLOGIES, INC. |
|          |   |   |   |
|          |   |   | BY: /s/ Chi Ming YU |
|          |   |   | Chi Ming YU, President and Director |
|          |   |   |   |
|          |   |   | BY: /s/ Wang Hui |
|          |   |   | Wang Hui, Director and Chief Executive Officer |
|          |   |   |   |
|          |   |   | BY: /s/ Kai GUI |
|          |   |   | Kai GUI, Director, Secretary and Chief Financial Officer |
|          |   |   |   |
|          |   |   |   |